ArticleBMC infectious diseases2025
Etiologic fraction of HPV-attributed anal and penile squamous cell carcinoma: study in specialized hospitals, Sri Lanka.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Human Papillomavirus (HPV) infection is known to cause anogenital cancers. Male HPV prevalence and Population Attributable Risk (PAR) are important to plan future HPV preventive strategies for HPV-driven anogenital cancers in males.
methodsA hospital-based case-control study was carried out to determine the etiologic fraction attributed to HPV-driven anal and penile(anogenital) cancers among male patients presenting to specialised hospitals in Gampaha district and Apeksha Hospital (cancer specialised) in Sri Lanka and to calculate the PAR percentage on anogenital Squamous Cell Cancer (SCC) among the study population where HPV prevalence was 5.7%. New or recently diagnosed anal and penile SCC patients (August 2022–June 2023) were included as cases. For each case, four controls were selected from sexually active, clinically normal men aged 20–70 years residing in Gampaha district. Additional etiological factors that were checked included the presence of sexually transmitted infections, phimosis, anogenital injury, and the use of tobacco, alcohol or illegal drugs. The Chi-square test was used at the significant level of p < 0.05 and the Fisher’s exact test was applied when expected cell counts were low. Bivariate and multivariable binary logistic regression analyses were used to calculate Odds Ratios (ORs).
resultsA significantly associated factor for getting anal or penile SCC was HPV infection (Adjusted OR(AOR) = 27.7; 95% CI: 4.3-177.8; P < 0.001). For any HPV genotype & High-Risk (HR) HPV genotype, the prevalence was 55% & 50% among cases, and 5% & 2.5% among controls, respectively. Assuming prevalence among controls as the population prevalence, the calculated PAR% was 60.3% for any HPV genotype and 39.4% for the HPV 16 h genotype.
conclusions60% of the anal and penile SCCs were attributed to any HPV genotype and a significant proportion (more than one-third) of anal and penile SCCs could potentially be prevented by introducing the HPV 16 genotype-containing vaccine to males. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.